Lifeline Cord Blood

By Amanda Gardner, HealthDay Reporter

Scientists have discovered a "cocktail" of growth factors that expands the number of stem cells they can grow in the laboratory at least 10 times beyond what anyone has been able to do before...

23/01/2006

The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit...

03/06/2009

BBC News

A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time. It is hoped that "master cells" taken from umbilical cords could be used on any patient without rejection...

Ko K. Maung ¹ Mitchell E. Horwitz ²

Ko K. Maung

KoKo.Maung@duke.edu

Mitchell E. Horwitz

Mitchell.Horwitz@duke.edu

1 Hematology and Medical Oncology Fellow, Duke University School of Medicine, 2400 Pratt St. DUMC 3961, Durham, NC 27710, USA

2 Adult Blood and Marrow Transplant Program, Duke University School of Medicine, 2400 Pratt St. DUMC 3961, Durham, NC 27710, USA

Clinical Research Division scientists have cleared a major technical hurdle to making umbilical cord blood transplants a more widely used method for treating leukemia and other blood cancers.

In a study published in the Jan. 17 edition of Nature Medicine, Dr. Colleen Delaney and colleagues describe the first use of a method to vastly expand the number of stem/progenitor cells from a unit of cord blood in the laboratory. When the cells were infused into patients, successful and rapid engraftment resulted.

The Gamida Cell-Teva Joint Venture announced today that the first patient in the international, pivotal registration ExCell study has undergone a StemEx® transplant at the Ireland Cancer Center of University Hospitals Case Medical Center. StemEx® is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells...

Physician-scientists at Johns Hopkins have developed a procedure called a half-matched bone marrow transplant that has been successful in “curing” patients of some cancers and blood disorders like sickle cell anemia...

By John Gever, Senior Editor, MedPage Today

SAN FRANCISCO, Dec. 8 -- Leukemia patients receiving umbilical cord blood stem cells expanded in the laboratory showed markedly faster engraftment compared with conventional transplant, a researcher said here...

cancerconsultants.com

Researchers from the University of Pittsburgh and Gamida Cell announced that the University of Pittsburgh would be participating in an international multicenter Phase III study of StemEx® for the treatment of hematologic malignancies...

HAIFA, Israel (BUSINESS WIRE)

Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced promising initial results of an animal model study using the company's innovative adjuvant cell therapy product known as PLX-1. PLX-1, by adding Mesenchymal Stromal Cells (MSC) during bone marrow transplant procedures that use...

05/07/2006

CINCINNATI, OHIO - Researchers from The University of Texas M. D. Anderson Cancer Center have found a therapy that effectively kills human leukemia cells in mice using natural killer (NK) cells from umbilical cord blood...

International stem cell scientists, co-led in Canada by Dr. John Dick and in the Netherlands by Dr. Gerald de Haan, have discovered the switch to harness the power of cord blood and potentially increase the supply of stem cells for cancer patients needing transplantation therapy to fight their disease.

Margaret Munro, CanWest News Service, Edmonton Journal

A life-saving stem-cell treatment has been given a boost by Canadian scientists, who've hit on a way to enhance production of the fabled cells. The team at the University of Western Ontario has shown an experimental drug can expand populations of stem cells in umbilical cord blood up to three times...

12/12/2005

Scientists at Fred Hutchinson Cancer Research Center have cleared a major technical hurdle to making umbilical-cord-blood transplants a more widely-used method for treating leukemia and other blood cancers. ..

Medical News Today

Researcher-scientists at The Saban Research Institute of Childrens Hospital Los Angeles have discovered a way to dramatically enhance the growth of stem cells from umbilical cord blood after transplantation, according to Gay Crooks, M.B., B.S., director of the Stem Cell Project at Childrens Hospital Los Angeles and a professor of pediatrics at the Keck School of Medicine of the University of Southern California (USC)...

ViaCell, Inc. (Nasdaq: VIAC) today announced that it has enrolled and treated the last patient in the CB001 Phase I clinical trial and has begun the 100-day post-transplant follow-up. CB001 is an investigational therapy being studied as a potential therapeutic option for people who need stem cell transplants, such as bone marrow, for hematopoietic recovery after...

25/07/2006